Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Europe Agreement on EC make-up could include cannabis-conservative health commissioner ...
  • Ukraine New additions to list of prohibited psychotropic substances ...
  • Germany BfArM published medical cannabis import data for for Q3 2024 ...
  • Denmark Government plans to make medical cannabis scheme permanent ...
  • United States Senate committee releases Farm Bill draft ...
  • Luxembourg Medical cannabis patients to see restrictions in 2025 ...
  • Moldova Passed amendment allows for registered hemp varieties to be cultivated ...
  • Germany Cannabis legalisation debate takes place ahead of snap elections ...
  • Ireland Ruling parties disagree on proposal to decriminalise personal drug use ...
  • Brazil Up to 0.3% THC in plants authorised for medical, pharmaceutical, industrial use ...
  • Australia Parliamentary committee makes suggestions for cannabis law in NSW ...
  • Australia Greens announce Parliament will vote on cannabis legalisation this month ...
View all
Regulatory reports

CBD classed as pharmaceutical product: Taiwan regulatory report

Written by || 24th January 2019 || Regulatory reports | Health and science | Marketing and retailing | Policy and Politics | Regulation and legislation | GeographiesAsia Taiwan

In our report looking at the regulations governing CBD in Taiwan, we find that CBD is a classified as a pharmaceutical product and the growing of cannabis plants for any purposes including the extraction, and the addition of CBD to cosmetic products, is prohibited.

Free Sample

Download a free sample page of the report

CBD classed as pharmaceutical product: Taiwan regulatory report

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Login

Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.